PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business

Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly

Eli Lilly has struck a deal allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on its platform.

12sources
12articles
10velocity
+271%since first seen
9d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📍 How it ended

Hims & Hers Health announced a partnership with Eli Lilly to sell the drugmaker's FDA-approved obesity medicines directly through the telehealth platform's website. The agreement, described by analysts as both surprising and inevitable, sent Hims & Hers shares surging on the day of the announcement.

Epilogue added 5d ago, after coverage quieted.

The brief

According to Reuters, Eli Lilly announced a partnership on Friday allowing Hims & Hers Health to offer its obesity medications Zepbound and Foundayo directly on the telehealth platform. Previously, patients could only access Lilly drugs on Hims & Hers by leaving the site and visiting Lilly's own cash-pay platform, LillyDirect. Reuters reported that this move sent the telehealth company's shares up by more than 7% in premarket trading. MarketWatch and Investor's Business Daily also noted the stock rally following the GLP-1 deal. This agreement aligns Lilly with its Danish rival Novo Nordisk, which has been selling Wegovy and Ozempic through Hims & Hers since March after previously suing the telehealth company over compounded versions. Leerink Partners analyst Michael Cherny called the Lilly partnership a clear positive, noting to Reuters that the deal completes Hims & Hers' process to secure access to the two leading GLP-1 drugmakers following its exit from mass compounding. Ilya Yuffa, president of Lilly USA, told Reuters that previously the ease and ability for someone on the platform to get Lilly medicine was not fully straightforward. Yuffa stated that any friction point for consumers increases the chance of abandonment. As part of the agreement, Yuffa told Reuters that Hims & Hers has agreed to stop selling any compounded versions or knockoffs of Lilly's obesity medications. Self-pay pricing starts at $299 per month for the injectable GLP-1 Zepbound and $149 per month for the oral Foundayo, matching prices on LillyDirect. Reuters reported that Novo's drugs on the platform start at $199 per month for the Wegovy injector pen and $149 per month for the Wegovy pill. According to Lilly, roughly 40% to 45% of Zepbound sales go through self-pay channels. Analysts told Reuters that Hims & Hers could receive a boost next year if employers drop weight-loss drug coverage to cut costs. Reuters noted that Lilly recently raised its full-year revenue forecast by $5 billion due to booming demand for its injectable weight-loss treatments, driving the company to a $1.2 trillion market valuation.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6d ago.

Quick answers

What drugs are included in the Hims & Hers and Eli Lilly deal?

The deal includes Eli Lilly's injectable Zepbound and its oral Foundayo.

How much do Lilly's obesity drugs cost on the Hims & Hers platform?

Self-pay pricing starts at $299 per month for Zepbound and $149 per month for Foundayo.

What did Hims & Hers agree to stop selling as part of the agreement?

Hims & Hers agreed not to sell any compounded versions or knockoffs of Lilly's obesity medications.

Coverage (12)

Topics

Related trends

\n \n \n \n \n \n \n